Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies (Q34156798)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

Alzheimer's disease

0 references

object named as

Alireza Atri

1

0 references

author name string

Susan D Rountree

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Oscar L Lopez

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Rachelle S Doody

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

10 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Neurodegenerative Diseases

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1-4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

170-174

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Predictors of long-term cognitive outcome in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Long-term course and effectiveness of combination therapy in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Cholinesterase inhibitors for Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Memantine for dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Long-term outcomes of galantamine treatment in patients with Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Rivastigmine in Alzheimer disease: efficacy over two years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

5 July 2018

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Long-term Outcome and Prediction Models of Activities of Daily Living in Alzheimer Disease With Cholinesterase Inhibitor Treatment

1 reference

https://api.crossref.org/works/10.1159%2F000335156

21 January 2018

Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

28 October 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3702018

28 October 2018

Identifiers

10.1159/000335156

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34156798&oldid=1976502800"